Zobrazeno 1 - 10
of 89
pro vyhledávání: '"R J, Fram"'
Autor:
R. J. Fram, J. Wilson, G. Strauss, Joel S. Greenberger, Sidney P. Kadish, D. Silver, P. Egan, Robert A. Lew, M. Liepman, Thomas J. Fitzgerald, D. Sherman, Lawrence D. Recht
Publikováno v:
American Journal of Clinical Oncology. 13:125-131
Thirty patients with histologically verified malignant supratentorial gliomas were treated with a preirradiation chemotherapy protocol consisting of two courses of intracarotid (i.c.) CDDP, 90 mg/m2, followed by i.v. BCNU, 200 mg/m2. Side effects fro
Autor:
H, Hamdalla, R J, Fram
Publikováno v:
Medicine and health, Rhode Island. 83(4)
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
Autor:
B A, Conley, M J, Egorin, N, Tait, D M, Rosen, E A, Sausville, G, Dover, R J, Fram, D A, Van Echo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(3)
Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions, induces differentiation and/or growth inhibit
Autor:
D, Glover, A, Lipton, A, Keller, A A, Miller, S, Browning, R J, Fram, S, George, K, Zelenakas, R S, Macerata, J J, Seaman
Publikováno v:
Cancer. 74(11)
Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patien
Publikováno v:
Cancer research. 50(1)
To study mechanisms underlying resistance to cis-diamminedichloroplatinum (II) (cis-DDP) we have induced resistance to this agent in BE human colon carcinoma cells. A 5-fold increase in the IC50 of resistant compared to sensitive cells was noted as a
Autor:
A. Qin, Alain C. Mita, Amita Patnaik, John Sarantopoulos, A. Ricart, Monica M. Mita, J. Watermill, Anthony W. Tolcher, R. J. Fram, K. K. Sankhala
Publikováno v:
Journal of Clinical Oncology. 25:3062-3062
3062 Background: HuC242-DM4 is a novel, targeted anti-cancer agent in development for the treatment of CanAg-expressing tumors such as carcinomas of the colon and pancreas. The compound is formed by the conjugation of the potent cytotoxic maytansinoi
Autor:
Frank V. Fossella, P. Fidias, J. McCann, R. Raju, Anthony W. Tolcher, Miguel A. Villalona-Calero, R. J. Fram, R. Guild, S. Zildjian
Publikováno v:
Journal of Clinical Oncology. 25:18084-18084
18084 Background: HuN901-DM1, a humanized antibody-maytansinoid immunoconjugagte, binds to CD56 which is expressed in almost all cases of SCLC as well as in other small cell carcinomas (SCC), neuroendocrine carcinomas, and multiple myeloma. The immun
Autor:
R. J. Fram, S. Sarantopolus, J. Watermill, A. Ricart, Alain C. Mita, Anthony W. Tolcher, S. Zildjian, Amita Patnaik, Monica M. Mita, J. Rodon
Publikováno v:
European Journal of Cancer Supplements. 4:66
Publikováno v:
Molecular pharmacology. 28(1)
Because cytotoxicity by an alkylating agent such as N-methyl-N'-nitrosoguanidine is markedly increased in adenine methylase-deficient dam-3 Escherichia coli, it was of interest to assess whether mismatch repair was similarly important in the repair o
Publikováno v:
Cancer research. 47(13)
Prior reports demonstrated more than additive cytotoxic effects of cis-diamminedichloroplatinum(II) (CDDP) and 1-beta-D-arabinofuranosylcytosine (ara-C) in LoVo colon carcinoma cells. We have extended these findings by analyzing mechanisms that may u